Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) – Pipeline Review, H2 2017’, provides in depth analysis on Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Central Nervous System, Immunology, Genetic Disorders, Toxicology, Dermatology and Infectious Disease under development targeting Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)

The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Celgene Corp

Chong Kun Dang Pharmaceutical Corp

Curis Inc

HitGen LTD

Kancera AB

Karus Therapeutics Ltd

Medivir AB

Merck & Co Inc

Millennium Pharmaceuticals Inc

OnKure Inc

Quimatryx SL

Shuttle Pharmaceuticals LLC

Sigma-Tau SpA

SK Biopharmaceuticals Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Overview 9

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Therapeutics Development 10

Products under Development by Stage of Development 10

Products under Development by Therapy Area 11

Products under Development by Indication 12

Products under Development by Companies 17

Products under Development by Universities/Institutes 24

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Therapeutics Assessment 26

Assessment by Mechanism of Action 26

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Companies Involved in Therapeutics Development 31

Celgene Corp 31

Chong Kun Dang Pharmaceutical Corp 32

Curis Inc 33

HitGen LTD 33

Kancera AB 34

Karus Therapeutics Ltd 34

Medivir AB 35

Merck & Co Inc 35

Millennium Pharmaceuticals Inc 36

OnKure Inc 37

Quimatryx SL 37

Shuttle Pharmaceuticals LLC 37

Sigma-Tau SpA 38

SK Biopharmaceuticals Co Ltd 38

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Drug Profiles 39

ACY-1083 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

ACY-738 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

ACY-775 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

C-1A - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

citarinostat - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

CKD-504 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

CKD-506 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

CKD-509 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

CKD-L - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

CUDC-907 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

HG-3001 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

IKH-12 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

KA-2507 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

KAN-0439221 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

KAN-0439782 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

MPT-0B291 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Nexturastat A - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

ONCO-101 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

QTX-125 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

QTX-153 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

remetinostat - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

ricolinostat - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Small Molecule to Inhibit HDAC6 for Oncology - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

Small Molecule to Inhibit HDAC6 for Oncology and Central Nervous System Disorders - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

Small Molecule to Inhibit HDAC6 for Sepsis - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

Small Molecules to Inhibit HDAC-6 for Autoimmune Disorders, Pancreatic Cancer and Charcot-Marie-Tooth Disease - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Small Molecules to Inhibit HDAC6 for Colorectal Cancer - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

Small Molecules to Inhibit HDAC6 for Neurodegenerative, Autoimmune and Inflammatory Diseases - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Small Molecules to Inhibit HDAC6 for Oncology - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

Small Molecules to Inhibit HDAC6 for Oncology and Immunology - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

Small Molecules to Inhibit Histone Deacetylase 6 for Oncology - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

SP-259 - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

ST-3595 - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

Synthetic Peptides to Inhibit HDAC6 for Oncology - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

vorinostat - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Dormant Products 96

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Product Development Milestones 99

Featured News & Press Releases 99

Sep 18, 2017: Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial 99

May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting 99

Apr 07, 2017: Medivir announces positive data from the phase II study of remetinostat in patients with early-stage cutaneous T-cell lymphoma 99

Mar 08, 2017: Regenacy Pharmaceuticals Demonstrates Reversal of Chemotherapy-Induced Peripheral Neuropathy with HDAC6 Inhibitor Ricolinostat in Preclinical Model 100

Dec 04, 2016: Acetylon Presents Early Phase 1a/1b Results for Citarinostat (ACY-241) in Combination with Pomalyst and Dexamethasone Showing Promising Treatment Responses in Relapsed or Relapsed-and-Refractory Multiple Myeloma 101

Dec 02, 2016: Acetylon to present data on Ricolinostat at the American Society of Hematology Annual Meeting 102

Dec 02, 2016: Acetylon to present data on ACY-738 at the American Society of Hematology Annual Meeting 103

Dec 02, 2016: Acetylon to present data on Citarinostat at the American Society of Hematology Annual Meeting 104

Jun 13, 2016: Acetylon Presents Data on the Use of HDAC6 Inhibitor Ricolinostat (ACY-1215) in Combination with Pomalidomide and Dexamethasone for the Treatment of Multiple Myeloma 105

Jun 13, 2016: Acetylon Presents Data on the Use of HDAC6 Inhibitor ACY-241 in Combination with Pomalidomide and Dexamethasone for the Treatment of Multiple Myeloma 106

Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association 107

Jun 03, 2016: Acetylon Collaborators Publish ASCO Abstracts Demonstrating Immunomodulatory Properties of Ricolinostat in Preclinical Melanoma Models 107

Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 108

Apr 20, 2016: Acetylon Announces the Presentation of Preclinical Data at AACR Supporting the Use of Selective HDAC6 Inhibition to Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology 109

Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 110

Appendix 111

Methodology 111

Coverage 111

Secondary Research 111

Primary Research 111

Expert Panel Validation 111

Contact Us 111

Disclaimer 112

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 10

Number of Products under Development by Therapy Areas, H2 2017 11

Number of Products under Development by Indications, H2 2017 13

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 15

Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 16

Number of Products under Development by Companies, H2 2017 17

Products under Development by Companies, H2 2017 18

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 19

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 20

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 21

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 22

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 23

Number of Products under Investigation by Universities/Institutes, H2 2017 24

Products under Investigation by Universities/Institutes, H2 2017 25

Number of Products by Stage and Mechanism of Actions, H2 2017 26

Number of Products by Stage and Route of Administration, H2 2017 28

Number of Products by Stage and Molecule Type, H2 2017 30

Pipeline by Celgene Corp, H2 2017 31

Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017 32

Pipeline by Curis Inc, H2 2017 33

Pipeline by HitGen LTD, H2 2017 34

Pipeline by Kancera AB, H2 2017 34

Pipeline by Karus Therapeutics Ltd, H2 2017 35

Pipeline by Medivir AB, H2 2017 35

Pipeline by Merck & Co Inc, H2 2017 36

Pipeline by Millennium Pharmaceuticals Inc, H2 2017 36

Pipeline by OnKure Inc, H2 2017 37

Pipeline by Quimatryx SL, H2 2017 37

Pipeline by Shuttle Pharmaceuticals LLC, H2 2017 38

Pipeline by Sigma-Tau SpA, H2 2017 38

Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017 38

Dormant Products, H2 2017 96

Dormant Products, H2 2017 (Contd..1), H2 2017 97

Dormant Products, H2 2017 (Contd..2), H2 2017 98

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 10

Number of Products under Development by Therapy Areas, H2 2017 11

Number of Products under Development by Top 10 Indications, H2 2017 12

Number of Products by Stage and Mechanism of Actions, H2 2017 26

Number of Products by Routes of Administration, H2 2017 27

Number of Products by Stage and Routes of Administration, H2 2017 27

Number of Products by Molecule Types, H2 2017 29

Number of Products by Stage and Molecule Types, H2 2017 29

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports